OncoMatch/Clinical Trials/NCT05404906
AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission
Is NCT05404906 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including Azacitidine and Venetoclax for acute myeloid leukemia (aml) in remission.
Treatment: Azacitidine · Venetoclax — This phase III trial is conducted to evaluate if azacitidine in combination with venetoclax as maintenance therapy improves relapse-free survival (RFS) for younger adults with favorable-risk acute myeloid leukemia (AML) who remained in first complete remission (CR1) following intensive consolidation.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Disease stage
Required: Stage FIRST REMISSION
are in their first remission
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Must have received: remission induction therapy
Patients who have received remission induction therapy
Must have received: cytarabine-based consolidation (cytarabine)
3-4 HiDAC or medium-dose cytarabine-based consolidation
Lab requirements
Kidney function
Creatinine Clearance Rate > or = 60 ml/min
Liver function
Serum total bilirubin <= 3 x ULN; AST and ALT <= 3 x ULN
Cardiac function
Left ventricular ejection fraction > or = 50% determined by ultrasound
Adequate organ function as follows: Serum total bilirubin <= 3 x ULN; AST and ALT <= 3 x ULN; Ccr (Creatinine Clearance Rate) > or = 60 ml/min; Left ventricular ejection fraction > or = 50% determined by ultrasound.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify